BR0314383A - Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) - Google Patents

Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)

Info

Publication number
BR0314383A
BR0314383A BR0314383-0A BR0314383A BR0314383A BR 0314383 A BR0314383 A BR 0314383A BR 0314383 A BR0314383 A BR 0314383A BR 0314383 A BR0314383 A BR 0314383A
Authority
BR
Brazil
Prior art keywords
tgf
oxazole
growth factor
transforming growth
inhibitors
Prior art date
Application number
BR0314383-0A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0314383A publication Critical patent/BR0314383A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

"COMPOSTOS DE OXAZOL E TIAZOL COMO INIBIDORES DO FATOR DE CRESCIMENTO TRANSFORMANTE (TGF)". A presente invenção descreve novos compostos de oxazol e tiazol, incluindo os seus derivados, intermediários para a sua preparação, composições farmacêuticas que os contêm e a sua utilização em medicina. Os compostos da presente invenção são inibidores potentes da via de sinalização do fator de crescimento transformante ('TGF')-<225>. São úteis no tratamento de várias doenças relacionadas com TGF-<225> incluindo, por exemplo, câncer e doenças fibróticas.
BR0314383-0A 2002-09-18 2003-09-08 Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) BR0314383A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02
PCT/IB2003/003823 WO2004026863A1 (en) 2002-09-18 2003-09-08 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
BR0314383A true BR0314383A (pt) 2005-07-19

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314383-0A BR0314383A (pt) 2002-09-18 2003-09-08 Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)

Country Status (28)

Country Link
US (1) US7273936B2 (pt)
EP (1) EP1542994B1 (pt)
JP (1) JP4518956B2 (pt)
KR (1) KR20050057415A (pt)
CN (1) CN1681810A (pt)
AP (1) AP2005003261A0 (pt)
AR (1) AR041273A1 (pt)
AT (1) ATE430147T1 (pt)
AU (1) AU2003256003A1 (pt)
BR (1) BR0314383A (pt)
CA (1) CA2499429C (pt)
CO (1) CO5550473A2 (pt)
CR (1) CR7743A (pt)
DE (1) DE60327443D1 (pt)
EA (1) EA200500354A1 (pt)
ES (1) ES2323421T3 (pt)
HR (1) HRP20050250A2 (pt)
IS (1) IS7711A (pt)
MA (1) MA27443A1 (pt)
MX (1) MXPA05002332A (pt)
NO (1) NO20051838L (pt)
OA (1) OA12926A (pt)
PA (1) PA8582701A1 (pt)
PE (1) PE20040987A1 (pt)
PL (1) PL375975A1 (pt)
TW (1) TW200413362A (pt)
UY (1) UY27978A1 (pt)
WO (1) WO2004026863A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
JP4519657B2 (ja) * 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物
CN1681805A (zh) * 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
ES2401138T3 (es) * 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
EP1798229A4 (en) * 2004-09-07 2009-07-29 Sankyo Co SUBSTITUTED BIPHENYL DERIVATIVE
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
WO2008150827A1 (en) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
WO2009111502A2 (en) 2008-03-03 2009-09-11 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
WO2009155388A1 (en) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
EP3638235A4 (en) * 2017-06-14 2021-06-09 Trevena, Inc. COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING IT
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena Inc COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
BR9809451A (pt) 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
AU9648098A (en) 1997-10-27 1999-05-17 Takeda Chemical Industries Ltd. Adenosine a3 receptor antagonists
WO2000061576A1 (en) * 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
WO2002051442A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
AP2005003260A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel triazole compounds as transforming growth factor (TGF) inhibitors.
JP4519657B2 (ja) 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物
CN1681805A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)

Also Published As

Publication number Publication date
AU2003256003A1 (en) 2004-04-08
EP1542994A1 (en) 2005-06-22
KR20050057415A (ko) 2005-06-16
DE60327443D1 (de) 2009-06-10
CO5550473A2 (es) 2005-08-31
HRP20050250A2 (en) 2005-10-31
WO2004026863A1 (en) 2004-04-01
NO20051838L (no) 2005-04-15
PA8582701A1 (es) 2004-04-23
IS7711A (is) 2005-02-24
TW200413362A (en) 2004-08-01
MXPA05002332A (es) 2005-06-08
EA200500354A1 (ru) 2005-10-27
MA27443A1 (fr) 2005-07-01
UY27978A1 (es) 2004-04-30
US7273936B2 (en) 2007-09-25
PE20040987A1 (es) 2004-12-27
CA2499429A1 (en) 2004-04-01
OA12926A (en) 2006-10-13
US20040110797A1 (en) 2004-06-10
ATE430147T1 (de) 2009-05-15
JP4518956B2 (ja) 2010-08-04
AR041273A1 (es) 2005-05-11
WO2004026863A8 (en) 2005-04-21
CA2499429C (en) 2010-09-21
EP1542994B1 (en) 2009-04-29
CR7743A (es) 2005-06-15
JP2006502235A (ja) 2006-01-19
PL375975A1 (en) 2005-12-12
AP2005003261A0 (en) 2005-03-31
CN1681810A (zh) 2005-10-12
ES2323421T3 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
BR0314383A (pt) Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
BR0314372A (pt) Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
BR0314286A (pt) Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf)
BR0314577A (pt) Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
BR0314302A (pt) Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
SE0200920D0 (sv) Novel compounds
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
TW200621762A (en) Novel compounds
NO20085077L (no) Nye forbindelser
SE0103836D0 (sv) Novel compounds
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
YU23202A (sh) Lekovi za tretman malignih tumora
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
BR0113590A (pt) 7-oxo-piridopirimidinas
BRPI0407055A (pt) Derivados de isotiazol
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
MXPA02001343A (es) Derivados de 6-azauracilo que inhiben interleucina-5.
SE9902551D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
SE0202692D0 (sv) Compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.